Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2008 May 5.
Published in final edited form as: DNA Repair (Amst). 2007 Jun 12;6(10):1463–1470. doi: 10.1016/j.dnarep.2007.04.013

Mutations affecting a putative MutLα endonuclease motif impact multiple mismatch repair functions

Naz Erdeniz a, Megan Nguyen a, Suzanne M Deschênes b, R Michael Liskay a,*
PMCID: PMC2366940  NIHMSID: NIHMS46350  PMID: 17567544

Abstract

Mutations in DNA mismatch repair (MMR) lead to increased mutation rates and higher recombination between similar, but not identical sequences, as well as resistance to certain DNA methylating agents. Recently, a component of human MMR machinery, MutLα, has been shown to display a latent endonuclease activity. The endonuclease active site appears to include a conserved motif, DQHA(X)2E(X)4E, within the COOH-terminus of human PMS2. Substitution of the glutamic acid residue (E705) abolished the endonuclease activity and mismatch-dependent excision in vitro. Previously, we showed that the PMS2-E705K mutation and the corresponding mutation in Saccharomyces cerevisiae were both recessive loss of function alleles for mutation avoidance in vivo. Here, we show that mutations impacting this endonuclease motif also significantly affect MMR-dependent suppression of homeologous recombination in yeast and responses to Sn1-type methylating agents in both yeast and mammalian cells. Thus, our in vivo results suggest that the endonuclease activity of MutLα is important not only in MMR-dependent mutation avoidance but also for recombination and damage response functions.

Keywords: Mismatch repair, MutLα, Endonuclease, Recombination, Methylation tolerance

1. Introduction

DNA mismatch repair (MMR) is a conserved process, which repairs mismatches generated during replication, by chemical damage and as “heteroduplex” intermediates during recombination [14]. The MMR system also suppresses recombination between similar but non-identical sequences, homeologous recombination [2,5]. Furthermore, in eukaryotes MMR plays a role in responses to certain types of DNA damage [1,68], in particular by Sn1-type DNA methylating agents [1,710]. Not surprisingly, MMR defects lead to a mutator phenotype, which in humans and mice is associated with increased cancer susceptibility, most notably hereditary nonpolyposis colon cancer (HNPCC) [1,1115].

The minimal human MMR system has been reconstituted in vitro with purified recombinant proteins, MutSα, MutLα, PCNA, RFC (the “clamp loader”), EXO1, RPA (HMGB1), polymerase δ and DNA ligase I [1618]. Similar to cell-free extracts, the in vitro repair is directed by a strand discontinuity (a nick or gap) that can be located either 5′ or 3′ of the mismatch. After recognition of mismatch, the mismatch-containing strand is degraded exonucleolytically from the pre-existing nick or gap and subsequently the resulting single-stranded gap is resynthesized and ligated. One of the essential components of the MMR machinery is MutLα, a heterodimer of MLH1 and PMS2 (Pms1 in yeast) [13,17,19]. Data from in vitro studies indicate that MutLα is recruited to the heteroduplex DNA in a MutSα-and ATP-dependent fashion and acts as an ATPase that coordinates protein conformational changes which are important for MMR [2023]. The in vitro studies further uncovered some of the specific MutLα functions, including enhancement of mismatch-dependent excision and participation in termination of excision upon mismatch removal [1618].

Recently, biochemical studies of reconstituted human and yeast MMR have demonstrated a latent endonuclease activity within MutLα [24, and personal communication, P. Modrich and T. Kunkel]. This endonuclease activity is activated by MutSα bound to the mismatch, ATP, PCNA and RFC. As a result, MutLα cleaves the discontinuous strand largely on the distal side of the mismatch, thus generating a mismatch-containing DNA fragment spanned by two nicks. Subsequently, this fragment is degraded by MutSα-activated EXO1. This endonuclease activity of MutLα can account for the observation that EXO1, which only possesses 5′ –3′ activity, is the only exonuclease required for the reconstituted in vitro MMR system, regardless of the position of the initiating nick with respect to the mispair [24,25].

The endonuclease active site of human MutLα includes a conserved motif, DQHA(X)2E(X)4E, within the COOH-terminus of PMS2 [24]. Substitution of either the aspartic (D699) or the glutamic acid residue (E705) abolished the endonuclease activity and mismatch-dependent excision [24]. We recently reported that the PMS2-E705K mutation and the corresponding mutation pms1-E707K (previously referred to as pms1-E738K) in the budding yeast Saccharomyces cerevisiae were both recessive mutations that crippled MMR-dependent mutational avoidance in vivo [26]. Here, we address the importance of the conserved endonuclease motif for additional MMR-dependent functions in budding yeast and mammalian cells. We show that mutations within the endonuclease motif significantly affect MMR-dependent suppression of homeologous recombination in yeast and responses to Sn1-type methylating agents in both yeast and mammalian cells. In addition, these findings have implications for the mechanisms of the damage response and recombination suppression by MMR.

2. Materials and methods

2.1. Media and growth conditions

All media were prepared as described [27] except that synthetic media contained increased leucine (60 mg/l). Growth and sporulation were at 30 °C. Sporulation of diploid cells and tetrad dissections were performed as described [28,29].

SJR1392 and derivatives were grown in YEPGE (2% glycerol, 2% ethanol and supplemented with 500 μg/ml adenine hemi-sulfate and 30 μg/ml tryptophan) [28]. For selection of His+ recombinants, S.D. medium lacking histidine was supplemented with 2% glycerol, 2% ethanol and 2% galactose as carbon sources (SGGE-His) [28].

2.2. Strain constructions

All yeast strains are derivatives of a RAD5 CAN1 W303-1B unless otherwise noted (see Table 1) [30,31]. W303 derivatives (CAN1, his1-7, his7-2, hom3-10, pms1Δ, pms1-E707K and rad52Δ) were described previously [29,32].

Table 1.

Strains used in this study

Strain Genotype Source
W1558-4A MATαade2-1 CAN1 his3-11,15 leu2-3,112 trp1-1 ura3-1 RAD5 [31]
NEY915 W1558 mgt1::TRP1 This study
NEY978 W1588 mgt1::TRP1 rad52::HIS5 This study
NEY981 W1588 mgt1::TRP1 rad52::HIS5 pms1::TRP1 This study
NEY1012 W1588 mgt1::TRP1 rad52::HIS5 pms1-E707K This study
NEY524 MATαade2-1 CAN1 his1-7 hom3-10 leu2-3,112 trpl-1 ura3-1 RAD5 [29]
NEY442 NEY524 pms1::TRP1 [29]
NEY1349 NEY524 pms1-E707K ade2-9G This study
NEY570 MATαade2-1 CAN1 his7-2 hom3-10 leu2-3,112 trp1-1 ura3-1 RAD5 [29]
NEY662 NEY524 pms1::TRP1 [29]
NEY1350 NEY524 pms1-E707K ade2-9G This study
SJR1392 MATαade2-101oc his3Δ 200 lys2Δ RV::hisG trp5 Δ::kan ura3(Nhe)-[HIS3::intron::cβ2/cβ7(91%)]-ura3(Nhe) leu2(K)-[lys2Δ3′-lys2Δ5′]-LEU2 Sue Jinks-Robertson
NEY644 SJR1392 pms1::URA3 This study
NEY1351 SJR1392 pms1-E707K This study

MGT1 disruption was constructed in haploid strains using a PCR-based gene disruption method [33] utilizing TRP1 as a selective marker and the following primers, with upper-case letter sequences complementary to MGT1 sequences and lowercase denoting selective marker sequences: MGT1-H1 (5′-AAAAAAATTG AAAACGGTCG CATTTTTGAT CTAAATGGAC CAACGgagcagattgtactgag-3′) and MTG1-H2 (5′-ACATAACTATTTCTTATGTTTATTTTCCTAAAATCCTTTATCCAA tgtgcggtatttcacacc-3′). The disruption was confirmed by PCR.

The introduction of pms1Δ and pms1-E707K into SJR1392 were performed as described previously [26,29].

2.3. Rate measurements and statistical analyses

The method of median was used to calculate the mutation rate [34]. Data from at least 20 independent cultures were used for each rate determination. Briefly, individual colonies from SJR1392 and its derivatives were grown in YEPGE medium for 3 days [28]. Aliquots of appropriate dilutions were plated onto synthetic complete medium (to determine viability of the cells), medium lacking histidine and glucose, but containing galactose, ethanol and glycerol (to select for homeologous recombinants) and medium lacking lysine (to select for homologous recombinants). Statistical analyses were performed using Prism 3.0 Software (GraphPad Software Inc.).

2.4. MNNG sensitivity by cytotoxicity and “spotting” assays

Sensitivity to a pulse of N-methyl-N′-nitro-N-nitrosoguanidine (MNNG; Sigma Chemical Co., St. Louis, MO) was determined by exposing exponentially growing yeast cells to varying amounts of MNNG for 45 min followed by plating of appropriate dilutions on YPD. Surviving colonies were counted after 3 days of incubation at 30 °C. For all strains, a plot of ln(survival%) versus dose yielded a straight line and an LD50 was calculated as −ln(2)/α, where α is the slope of the straight line.

For spotting assays, relevant yeast strains were grown overnight to saturation in YPD, serially diluted (1:5) and spotted with a 48-prong replicator onto synthetic complete medium (CSM) and CSM containing 0.35 μM MNNG plates and grown at 30 °C for 2 days.

For microscopy, logarithmatically growing liquid yeast cultures were exposed to 0.5 μM MNNG for 45 min followed by washing and resuspending of the yeast culture in fresh media. Aliquots of each culture were taken at appropiate time points. Cells were harvested by centrifugation and fixed with methanol/acetic acid (3:1 ratio) for 0.5 h on ice and stained with 4′,6-diamino-2-phenylindole (DAPI, Accurate Biochemicals and Scientific Corp., Westbury, NY) for 5 min at room temperature. Images were collected using a Zeiss Axiovert LSM5 Pascal laser-scanning microscope. At least 100 cells were counted for each sample and each experiment was done in duplicate.

2.5. Culturing of mouse cell lines and 6-tg treatment

Spontaneously-immortalized mouse embryonic fibroblast (MEF) cell lines used in this study were derived from Pms2−/− C18 cells and grown as previously described [22,26,35].

Sensitivity to a “pulse” treatment of 6-tg (2-amino-6-mercaptopurine; Sigma Chemical Co.) was determined by exposing exponentially growing cells to different concentrations of 6-tg diluted into complete medium. Following a 24 h treatment at 37 °C, cells were rinsed once with 5 ml of PBS and refed with complete medium. After 8 days, cell colonies were fixed in 30% ethanol 50% methanol, stained with 0.25% methylene blue and counted. For each dose, three 100-mm plates were analyzed, seeded with either 300, 600 or 1000 cells. Each cell line was tested in three independent experiments, and the colony-forming units (CFUs) at each dose were averaged. For all strains, a plot of ln(survival%) versus dose yielded a straight line and an LD50 was calculated as −ln(2)/α, where α is the slope of the straight line.

2.6. Western blot analysis

Whole cell lysates from cultured cells were prepared and 50 μg of total cellular protein were used for Western blot analysis as described previously [26,35]. hPms2 and mMsh6 proteins were detected with monoclonal antibodies A16-4 and clone 44, respectively (BD Pharmingen).

3. Results and Discussion

Recent in vitro studies suggest that the endonuclease active site of human MutLα includes a conserved motif, DQHA(X)2E(X)4E [24], within the MLH1-interaction domain of PMS2 (Fig. 1a, [36]). Substitution of the first glutamic acid residue (E705) abolishes the endonuclease activity of human MutLα [24]. However, this substitution does not detectably affect either yeast Pms1/Mlh1 or human PMS2/MLH1 interactions, the stability of Pms1 or PMS2 [26] or interaction of MutLα with MutSα on a mismatch (personal communication, P. Modrich and T. Kunkel). Nevertheless, we cannot exclude the possibility that this substitution might affect other functions of MutLα such as interactions with unknown proteins. Our previous in vivo studies showed that the E705K mutation in human PMS2 and the corresponding mutation E707K in the PMS1 gene of S. cerevisiae were both recessive loss of function mutations for MMR spellchecker activity [26]. Please note that in contrast to our previous report [26], we now designate the relevant glutamic acid as residue 707 in accordance with the Stanford S. cerevisiae data base. Here, we have addressed the importance of this conserved endonuclease motif for additional MMR-dependent functions in budding yeast and mammalian cells.

Fig. 1.

Fig. 1

(a) Pms1/2 domains and location of E707/E705. The ATPase domain, the Mlh1-interacting domain and a motif critical for MutLα endonuclease activity are indicated by hatched, black and grey boxes, respectively. The “mutated” E707/E705 residue is indicated by an arrow. Numbers correspond to the amino acid position in the protein in accordance with the current data bases. (b) Papillation phenotypes of the wild type, pms1Δ, pms1-E707K strains. The relative mutator effects in wild type, pms1Δ, pms1-E707K strains were detected by monitoring forward mutation at CAN1 (multiple types of mutations) vs. reversion at his1-7 (intragenic missense suppressor mutations), his7-2 (+1 bp frameshifts in a stretch of 7A/T bp) or hom3-10 (−1 bp frameshifts in a stretch of 7A/T bp) by replica plating onto appropriate selective media. It should be noted that pms1Δ strains contain ade2-1 that results in solid red colored papilliae, whereas pms1-E707K strains contain a ade2-9G (+1 bp frameshift in a stretch of 9G/C bp) reporter that gives rise to red/white papilliae due to DNA polymerase slippage in the 9 G/C run.

3.1. pms1-E707K cripples MMR of different types of mispairs

Our previous study using a single mutation reporter (i.e., hom3-10) showed that the pms1-E707K allele elevated −1 bp frameshifts to a level similar to a pms1Δ strain [26]. To gain additional insight into the role of the endonuclease motif for MMR-dependent mutation avoidance in yeast, we measured mutation in the pms1-E707K strain using four different mutator assays [29]: forward mutation to canavanine-resistance at CAN1 that reports multiple types of mutations, his1-798 (his1-7) reversion that reports base substitution (intragenic suppressor) mutations, his7-2 reversion that reports +1 bp frameshifts in a run of 7A/T bp and hom3-10 reversion that reports −1 bp frameshifts in a 7A/T run. Previous work demonstrated that elevation of mutation in each assay in a pms1Δ strain can be visualized by increased number of papillae on the appropriate selective media (Fig. 1b). As shown in Fig. 1b, the number of papillae observed with the pms1-E707K strain was similar to pms1Δ in each assay. Therefore, these results suggest that the endonuclease activity of MutLα is required for the repair of a variety of mispairs.

3.2. pms1-E707K impacts the suppression of homeologous recombination

The role of MMR proteins in the suppression of homeologous recombination is well-established in yeast, although the mechanism of suppression, including the role of MutLα, is not clear [2,5]. To address whether the endonuclease activity of MutLα is important for suppression of homeologous recombination, the pms1-E707K allele was introduced into the PMS1 locus of a haploid yeast strain (SJR1392), which contains reporters that measure rates of homeologous versus homologous recombination between inverted repeats [28]. We measured the rates of homeologous recombination and homologous recombination by selecting for inversion events that reconstitute full-length HIS3 and LYS2 genes, respectively. As shown in Table 2, pms1Δ significantly increased the homeologous recombination rate, without elevating homologous recombination. Normalized to homologous recombination, the increase in the homeologous recombination was 24-fold in the pms1Δ mutant relative to PMS1.

Table 2.

Effect of pms1-E707K on homeologous recombination

Strain Homologous (Lys+, × 10−6) Homeologous (His+, × 10−6) His+/Lys+
PMS1 5.0 (4.1–5.9) 0.07 (0.051–0.089) 0.014 [1]
pms1Δ 7.4 (6.2–8.5) 2.42 (1.8–3.0) 0.33 [24]
pms1-E707K 12.6 (8.6–17) 1.35 (1.1–1.6) 0.11 [8]

( ) 95% Confidence intervals; [ ] fold effects relative to PMS1.

Similarly, pms1-E707K elevated the homeologous recombination rate by 8-fold relative to the wild type. These results suggest that the endonuclease activity of yeast MutLα contributes to the suppression of homeologous recombination.

Genetic requirements of suppression of yeast homeologous recombination have been examined in great detail [2,5]. In particular, the suppressive role of MutLα seems less than that of MutSα, because msh2Δ has a greater “elevating” effect on homeologous recombination than either pms1Δ or mlh1Δ [3739]. Therefore, mismatch binding/recognition may be sufficient to trigger some level of recombination suppression in yeast. Although the exact role of MutLα in homeologous recombination suppression is unknown, our results with the pms1-E707K allele suggest that the endonuclease activity of MutLα is important. It is interesting to note that the effect of pms1Δ allele on homeologus recombination appears to be greater than the pms1-E707K allele. Therefore, MutLα appears to contribute to the suppression of homeologous recombination by both endonuclease-dependent and -independent actions. We suggest that the endonuclease-dependent contribution may reflect events containing mismatched hDNA intermediates in which a single strand interruption 3′ to the mismatch(es) provides an entry point for MMR-mediated suppression.

3.3. pms1-E707K (PMS2-E705) compromises the MMR-dependent DNA damage responses in yeast and mammalian cells

In mammalian cells, MMR also participates in cytotoxic and cell cycle arrest responses to certain classes of DNA damaging agents, most notably Sn1-type methylating agents [1,710]. Mammalian cells deficient in MMR show increased resistance to the cytotoxic effects of Sn1-type methylating agents, such as nitrosoguanidine (MNNG) and the methylation mimetic drug, 6-thioguanine (6-tg) [8,4042]. Recently, a similar MMR-dependent response was demonstrated in yeast cells that were defective in both homologous recombination (rad52Δ) and the methylguanine methyltransferase (mgt1Δ) [43]. This is illustrated in Fig. 2a and b, which shows that whereas a rad52Δ mgt1Δ strain was highly sensitive to MNNG, the MMR defective rad52Δ mgt1Δ pms1Δ strain was resistant.

Fig. 2.

Fig. 2

MNNG-induced killing of rad52Δ mgt1Δ, rad52Δ mgt1Δ pms1Δ and rad52Δ mgt1Δ pms1-E707K yeast strains: (a) comparison of MNNG responses for wild type, mgt1Δ, rad52Δ and pms1 mutants in combinations as measured by a serial dilution spot test. Late-log phase cells were spotted on CSM and CSM + 0.35 μM MNNG plates at 5-fold serial dilutions as described in the Section 2. (b) MNNG survival curves. mgt1Δ (■), rad52Δ mgt1Δ pms1Δ (▲), rad52Δ mgt1Δ pms1-E707K (●) and rad52Δ mgt1Δ (♦) strains were exposed for 45 min to increasing amounts of MNNG and survival was determined. Error bars represent standard error of the mean. LD50 values for mgt1Δ, rad52Δ mgt1Δ pms1Δ, rad52 mgt1Δ pms1-E707K and rad52Δ mgt1Δ strains were 9.7, 1.8, 1.5 and 0.25 μM MNNG, respectively.

To ask whether the endonuclease activity of MutLα is required for the damage response pathway in yeast, we compared the cytotoxic responses of the rad52Δ mgt1Δ, rad52Δ mgt1Δ pms1Δ and rad52Δ mgt1Δ pms1-E707K strains to MNNG. As shown in Fig. 2a, even at relatively low doses, the rad52Δ mgt1Δ pms1-E707K strain displayed a level of resistance to MNNG similar to that observed for rad52Δ mgt1Δ pms1Δ. This finding was further confirmed by calculating the LD50 values(i.e., 50% survival) for each strain at a range of MNNG doses. Whereas the LD50 of rad52Δ mgt1Δ strains was 0.25 μM, the LD50 of the rad52Δ mgt1Δ pms1Δ and rad52 mgt1Δ pms1-E707K strains were 1.8 and 1.5 μM, respectively. These observations suggest that the endonuclease activity of yeast MutLα is required for the cytotoxic response to Sn1-type methylating agents.

In cultured mammalian cells, MMR-dependent responses to Sn1-type methylating agents are associated with G2 cell cycle arrest [8,35,44]. To determine whether yeast show a similar cell cycle arrest, we microscopically monitored logarithmically growing rad52Δ mgt1Δ, rad52Δ mgt1Δ pms1Δ and rad52Δ mgt1Δ pms1-E707K strains following treatment with 0.5 μM MNNG, a concentration that results in ~ 70% killing of the rad52Δ mgt1Δ cells with little effect on either the rad52Δ mgt1Δ pms1Δ or rad52Δ mgt1Δ pms1-E707K strain (see Fig. 2b). Cells were harvested at various times, fixed and stained with DAPI to visualize nuclear morphology. Within 2 h of MNNG treatment, the rad52Δ mgt1 Δ cells accumulated with a nuclear and budding morphology characteristic of G2/M arrested yeast (see Fig. 3). In contrast, rad52Δ mgt1Δ pms1Δ and rad52Δ mgt1Δ pms1-E707K cells both grew normally in MNNG. These results indicate that the response to MNNG in yeast is associated with a G2/M arrest, consistent with observations in mammalian cells.

Fig. 3.

Fig. 3

Cell cycle arrest phenotype of rad52Δ mgt1Δ mutant strains after exposure to MNNG. After 45 min exposure to 0.5 μM MNNG, cells from rad52Δ mgt1Δ, rad52Δ mgt1Δ pms1Δ and rad52Δ mgt1Δ pms1-E707K cultures were collected every hour, fixed and stained with DAPI: (a) after 2 h, rad52Δ mgt1Δ accumulated as large-budded cells with a single nucleus and (b) quantification of cell cycle arrest after MNNG exposure. Distribution of cells from rad52Δ mgt1Δ, rad52Δ mgt1Δ pms1Δ and rad52Δ mgt1Δ pms1-E707K cultures after exposure to MNNG are depicted as percentages. Cells were divided into categories as cells with no buds, small buds, large buds and divided cells. For each time point, at least 100 cells were counted in two separate experiments.

Previous studies showed that Pms2-null kidney [45] and mouse embryonic fibroblasts cells (Buermeyer and Liskay, unpublished results) were resistant to the cytotoxic effects of 6-thioguanine (6-tg), a Sn1-type methylation mimetic drug [46,47]. Therefore, we determined the colony-forming ability of Pms2−/− null mouse embryonic fibroblasts (MEF) stably expressing empty vector, wild type hPMS2 or hPMS2-E705K after 24 h exposure to different concentrations of 6-tg (Fig. 4a). Two cell lines that expressed hPMS2 at different levels were highly sensitive to 6-tg relative to the Pms2-null cell lines (Fig. 4, compare LD50 of 0.28 μM 6-tg for hPMS2 lines versus LD50 of 1.33 μM 6-tg for the Pms2-null), indicating that expression of wild type Pms2 within this range is sufficient for the normal response to 6-tg. Similar to the Pms2-null cells, cells expressing hPMS2-E705K were highly resistant to 6-tg, showing an LD50 of 1.31. These results suggest that, similar to budding yeast, the endonuclease activity of human MutLα is required for the MMR-dependent DNA damage response to Sn1-type methylating agents.

Fig. 4.

Fig. 4

Survival of MEFs after treatment with 6-tg: (a) 8 days after a 24 h exposure to 6-tg, CFU were determined for Pms2-deficient (♦), hPMS2-E705K expressing (▲) and low and high hPMS2-expressing (■, ●) MEF cells. Error bars represent standard error of the mean. LD50 values were 1.33, 1.31, and 0.28 μM 6-tg for Pms2-deficient, hPMS2-E705K expressing and low hPMS2-expressing MEF cells, respectively. (b) Expression of hPMS2 and hPMS2-E705K in stably-transfected MEFs. To determine the level of hPMS2-E705K vs. wild type hPMS2 expression levels in MEFs, whole cell lysates were prepared and compared by Western analysis. Endogenous Msh6 expression was used to normalize hPMS2 expression.

Two contrasting, but not mutually exclusive models, have been proposed for the MMR-dependent response to Sn1-type methylating agents in mammalian cells [3,10,42,48]. The first model, termed “futile repair”, invokes repeated cycles of MMR on O6meG/T formed during replication. Repeated cycles fail to remove damage in the template strand that in turn may lead to double strand breaks [8]. In contrast, in the “direct signaling” model MMR protein complexes bound to O6meG/T mispairs act as direct sensors to signal for cell cycle checkpoint arrest and/or apoptosis [3,10,42,48].

Support for the futile cycling model comes from several studies including in vitro results showing reiterative MMR excision cycles on O6meG/T containing plasmid substrates [49]. In contrast, support for direct signaling comes in part from a “separation-of-function” allele of mouse Msh6 that impacts spellchecking with little or no effect on the MMR-dependent DNA damage response [50]. The signaling model is also supported by the demonstration that MutSα/MutLα complexes are required for the recruitment of ATR–ATRIP to methylation damage sites (O6meG/T mispairs) and subsequent ATR kinase activation [51]. The results reported here appear consistent with futile repair because a defective endonuclease can be expected to impede repeated cycles of MMR-dependent excision.

In summary, by altering a conserved motif in both yeast Pms1 and human PMS2, we asked whether the endonuclease of yeast and human MutLα is important for several MMR-dependent functions. We draw several conclusions from our study. First, the MutLα endonuclease of yeast is required for the repair of a variety of different types of mispairs. Second, the MutLα endonuclease of yeast contributes to the suppression of homeologous recombination. And third, in both yeast and mammalian cells, the endonuclease activity of MutLα is required for the MMR-dependent response to DNA methylation damage.

Acknowledgments

We thank Sue Jinks-Robertson, Marcel Wehrli, Jennifer Johnson, Ashleigh Miller and Sandra Dudley for critical reading of the manuscript. This work was supported by National Institutes of Health grant 5R01 GM45413 to RML.

References

  • 1.Buermeyer AB, Deschenes SM, Baker SM, Liskay RM. Mammalian DNA mismatch repair. Annu Rev Genet. 1999;33:533–564. doi: 10.1146/annurev.genet.33.1.533. [DOI] [PubMed] [Google Scholar]
  • 2.Harfe BD, Jinks-Robertson S. DNA mismatch repair and genetic instability. Annu Rev Genet. 2000;34:359–399. doi: 10.1146/annurev.genet.34.1.359. [DOI] [PubMed] [Google Scholar]
  • 3.Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol. 2006;7:335–346. doi: 10.1038/nrm1907. [DOI] [PubMed] [Google Scholar]
  • 4.Modrich P, Lahue R. Mismatch repair in replication fidelity, genetic recombination and cancer biology. Annu Rev Biochem. 1996;65:101–133. doi: 10.1146/annurev.bi.65.070196.000533. [DOI] [PubMed] [Google Scholar]
  • 5.Harfe BD, Jinks-Robertson S. Mismatch repair proteins and mitotic genome stability. Mutat Res. 2000;451:151–167. doi: 10.1016/s0027-5107(00)00047-6. [DOI] [PubMed] [Google Scholar]
  • 6.Bellacosa A. Functional interactions and signaling properties of mammalian DNA mismatch repair proteins. Cell Death Differ. 2001;8:1076–1092. doi: 10.1038/sj.cdd.4400948. [DOI] [PubMed] [Google Scholar]
  • 7.Brown KD, Rathi A, Kamath R, Beardsley DI, Zhan Q, Mannino JL, Baskaran R. The mismatch repair system is required for S-phase checkpoint activation. Nat Genet. 2003;33:80–84. doi: 10.1038/ng1052. [DOI] [PubMed] [Google Scholar]
  • 8.Stojic L, Brun R, Jiricny J. Mismatch repair and DNA damage signalling. DNA Repair (Amst) 2004;3:1091–1101. doi: 10.1016/j.dnarep.2004.06.006. [DOI] [PubMed] [Google Scholar]
  • 9.Bellacosa A. Role of MED1 (MBD4) gene in DNA repair and human cancer. J Cell Physiol. 2001;187:137–144. doi: 10.1002/jcp.1064. [DOI] [PubMed] [Google Scholar]
  • 10.Fishel R. Signaling mismatch repair in cancer. Nat Med. 1999;5:1239–1241. doi: 10.1038/15191. [DOI] [PubMed] [Google Scholar]
  • 11.Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, Kane M, Earabino C, Lipford J, Lindblom A, Tannergard P, Bollag RJ, Godwin AR, Ward DC, Nordenskjold M, Fishel R, Kolodner R, Liskay RM. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary nonpolyposis colon cancer. Nature. 1994;368:258–261. doi: 10.1038/368258a0. [DOI] [PubMed] [Google Scholar]
  • 12.Edelmann L, Edelmann W. Loss of DNA mismatch repair function and cancer predisposition in the mouse: animal models for human hereditary nonpolyposis colorectal cancer. Am J Med Genet C Semin Med Genet. 2004;129:91–99. doi: 10.1002/ajmg.c.30021. [DOI] [PubMed] [Google Scholar]
  • 13.Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell. 1993;75:1027–1038. doi: 10.1016/0092-8674(93)90546-3. [DOI] [PubMed] [Google Scholar]
  • 14.Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, Peltomaki P, Sistonen P, Aaltonen LA, Nystrom-Lahti M, Guan X-Y, Zhang J, Meltzer PS, Yu J-W, Kao F-T, Chen DJ, Cerosaletti KM, Fournier REK, Todd S, Lewis T, Leach RJ, Naylor SL, Weissenbach J, Mecklin J-P, Jarvinen H, Petersen GM, Hamilton SR, Green J, Jass J, Watson P, Lynch HT, Trent JM, de la Chapelle A, Kinzler KW, Vogelstein B. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell. 1993;75:1215–1225. doi: 10.1016/0092-8674(93)90330-s. [DOI] [PubMed] [Google Scholar]
  • 15.Papadopoulos N, Nicolaides NC, Wei Y-F, Ruben SM, Carter KC, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM, Adams MD, Venter JC, Hamilton SR, Petersen GM, Watson P, Lynch HT, Peltomaki P, Mecklin J-P, de la Chapelle A, Kinzler KW, Vogelstein B. Mutation of a mutL homolog in hereditary colon cancer. Science. 1994;263:1625–1629. doi: 10.1126/science.8128251. [DOI] [PubMed] [Google Scholar]
  • 16.Constantin N, Dzantiev L, Kadyrov FA, Modrich P. Human mismatch repair: reconstitution of a nick-directed bidirectional reaction. J Biol Chem. 2005;280:39752–39761. doi: 10.1074/jbc.M509701200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Modrich P. Mechanisms in eukaryotic mismatch repair. J Biol Chem. 2006;281:30305–30309. doi: 10.1074/jbc.R600022200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Zhang Y, Yuan F, Presnell SR, Tian K, Gao Y, Tomkinson AE, Gu L, Li GM. Reconstitution of 5′-directed human mismatch repair in a purified system. Cell. 2005;122:693–705. doi: 10.1016/j.cell.2005.06.027. [DOI] [PubMed] [Google Scholar]
  • 19.Prolla T, Christie D-M, Liskay RM. Dual requirement in yeast DNA mismatch repair for MLH1 and PMS1, two homologs of the bacterial mutL gene. Mol Cell Biol. 1994;14:407–415. doi: 10.1128/mcb.14.1.407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Raschle M, Marra G, Nystrom-Lahti M, Schar P, Jiricny J. Identification of hMutLbeta, a heterodimer of hMLH1 and hPMS1. J Biol Chem. 1999;274:32368–32375. doi: 10.1074/jbc.274.45.32368. [DOI] [PubMed] [Google Scholar]
  • 21.Hall MC, Kunkel TA. Purification of eukaryotic MutL homologs from Saccharomyces cerevisiae using self-affinity technology. Protein Expr Purif. 2001;21:333–342. doi: 10.1006/prep.2000.1379. [DOI] [PubMed] [Google Scholar]
  • 22.Tomer G, Buermeyer AB, Nguyen MM, Liskay RM. Contribution of human Mlh1 and Pms2 ATPase activities to DNA mismatch repair. J Biol Chem. 2002;277:21801–21809. doi: 10.1074/jbc.M111342200. [DOI] [PubMed] [Google Scholar]
  • 23.Mol Med Genet. Oregon Health Sciences University; Portland: 2001. P.T. Tran Functional studies on the candidate ATPase domains of Saccharomyces cerevisiae MutLα; pp. 1–119. [Google Scholar]
  • 24.Kadyrov FA, Dzantiev L, Constantin N, Modrich P. Endonucleolytic function of MutLα in human mismatch repair. Cell. 2006;126:297–308. doi: 10.1016/j.cell.2006.05.039. [DOI] [PubMed] [Google Scholar]
  • 25.Genschel J, Modrich P. Mechanism of 5′-directed excision in human mismatch repair. Mol Cell. 2003;12:1077–1086. doi: 10.1016/s1097-2765(03)00428-3. [DOI] [PubMed] [Google Scholar]
  • 26.Deschenes SM, Tomer G, Nguyen M, Erdeniz N, Juba NC, Sepulveda N, Pisani JE, Michael Liskay R. The E705K mutation in hPMS2 exerts recessive, not dominant, effects on mismatch repair. Cancer Lett. 2006;249:148–156. doi: 10.1016/j.canlet.2006.08.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Sherman F. Getting started with yeast. Methods Enzymol. 1991;194:3–21. doi: 10.1016/0076-6879(91)94004-v. [DOI] [PubMed] [Google Scholar]
  • 28.Welz-Voegel C, Stone JE, Tran P, Kearney HM, Liskay RM, Petes TD, Jinks-Robertson S. Alleles of the yeast PMS1 mismatch repair gene that differentially affect recombination- and replication-related processes. Genetics. 2002;162:1131–1145. doi: 10.1093/genetics/162.3.1131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Erdeniz N, Dudley S, Gealy R, Jinks-Robertson S, Liskay RM. Novel PMS1 alleles preferentially affect the repair of primer strand loops during DNA replication. Mol Cell Biol. 2005;25:9221–9231. doi: 10.1128/MCB.25.21.9221-9231.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Thomas BJ, Rothstein R. Elevated recombination rates in transcriptionally active DNA. Cell. 1989;56:619–630. doi: 10.1016/0092-8674(89)90584-9. [DOI] [PubMed] [Google Scholar]
  • 31.Zou H, Rothstein R. Holiday junctions accumulate in replication mutants via a RecA homolog-independent mechanism. Cell. 1997;90:87–96. doi: 10.1016/s0092-8674(00)80316-5. [DOI] [PubMed] [Google Scholar]
  • 32.Smith J, Rothstein R. An allele of RFA1 suppresses RAD52-dependent double-strand break repair in Saccharomyces cerevisiae. Genetics. 1999;151:447–458. doi: 10.1093/genetics/151.2.447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Baudin A, Ozier-Kalogeropoulos O, Denouel A, Lacroute F, Cullin C. A simple and efficient method for direct gene deletion in Saccharomyces cerevisiae. Nucl Acids Res. 1993;21:3329–3330. doi: 10.1093/nar/21.14.3329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Lea D, Coulson C. The distribution of the number of mutants in bacterial populations. J Genet. 1948;49:264–285. doi: 10.1007/BF02986080. [DOI] [PubMed] [Google Scholar]
  • 35.Buermeyer AB, Wilson-Van Patten C, Baker SM, Liskay RM. The human MLH1 cDNA complements DNA mismatch repair defects in Mlh1-deficient mouse embryonic fibroblasts. Cancer Res. 1999;59:538–541. [PubMed] [Google Scholar]
  • 36.Pang Q, Prolla TA, Liskay RM. Functional domains of the Saccharomyces cerevisiae MLH1 and PMS1 DNA mismatch repair proteins and their relevance to hereditary nonpolyposis colorectal cancer-associated mutations. Mol Cell Biol. 1997;17:4465–4473. doi: 10.1128/mcb.17.8.4465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Chen W, Jinks-Robertson S. Mismatch repair proteins regulate heteroduplex formation during mitotic recombination in yeast. Mol Cell Biol. 1998;18:6525–6537. doi: 10.1128/mcb.18.11.6525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Nicholson A, Hendrix M, Jinks-Robertson S, Crouse GF. Regulation of mitotic homeologous recombination in yeast. Functions of mismatch repair and nucleotide excision repair genes. Genetics. 2000;154:133–146. doi: 10.1093/genetics/154.1.133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Spell RM, Jinks-Robertson S. Role of mismatch repair in the fidelity of RAD51- and RAD59-dependent recombination in Saccharomyces cerevisiae. Genetics. 2003;165:1733–1744. doi: 10.1093/genetics/165.4.1733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Jun SH, Kim TG, Ban C. DNA mismatch repair system. Classical and fresh roles. FEBS J. 2006;273:1609–1619. doi: 10.1111/j.1742-4658.2006.05190.x. [DOI] [PubMed] [Google Scholar]
  • 41.Karran P, Hampson R. Genomic instability and tolerance to alkylating agents. Cancer Surv. 1996;28:69–85. [PubMed] [Google Scholar]
  • 42.Wang JY, Edelmann W. Mismatch repair proteins as sensors of alkylation DNA damage. Cancer Cell. 2006;9:417–418. doi: 10.1016/j.ccr.2006.05.013. [DOI] [PubMed] [Google Scholar]
  • 43.Cejka P, Mojas N, Gillet L, Schar P, Jiricny J. Homologous recombination rescues mismatch-repair-dependent cytotoxicity of S(N)1-type methylating agents in S. cerevisiae. Curr Biol. 2005;5:1395–1400. doi: 10.1016/j.cub.2005.07.032. [DOI] [PubMed] [Google Scholar]
  • 44.Hawn MT, Umar A, Carethers JM, Marra G, Kunkel TA, Boland CR, Koi M. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Res. 1995;55:3721–3725. [PubMed] [Google Scholar]
  • 45.Shin CY, Ponomareva ON, Connolly L, Turker MS. A mouse kidney cell line with a G:C → C:G transversion mutator phenotype. Mutat Res. 2002;503:69–76. doi: 10.1016/s0027-5107(02)00073-8. [DOI] [PubMed] [Google Scholar]
  • 46.Glaab WE, Risinger JI, Umar A, Barrett JC, Kunkel TA, Tindall KR. Resistance to 6-thioguanine in mismatch repair-deficient human cancer cell lines correlates with an increase in induced mutations at the HPRT locus. Carcinogenesis. 1998;19:1931–1937. doi: 10.1093/carcin/19.11.1931. [DOI] [PubMed] [Google Scholar]
  • 47.Waters TR, Swann PF. Cytotoxic mechanism of 6-thioguanine: hMutSα, the human mismatch binding heterodimer, binds to DNA containing S6-methylthioguanine. Biochemistry. 1997;36:2501–2506. doi: 10.1021/bi9621573. [DOI] [PubMed] [Google Scholar]
  • 48.Iyer RR, Pluciennik A, Burdett V, Modrich PL. DNA mismatch repair: functions and mechanisms. Chem Rev. 2006;106:302–323. doi: 10.1021/cr0404794. [DOI] [PubMed] [Google Scholar]
  • 49.York SJ, Modrich P. Mismatch repair-dependent iterative excision at irreparable O6-methylguanine lesions in human nuclear extracts. J Biol Chem. 2006;281:22674–22683. doi: 10.1074/jbc.M603667200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Yang G, Scherer SJ, Shell SS, Yang K, Kim M, Lipkin M, Kucherlapati R, Kolodner RD, Edelmann W. Dominant effects of an Msh6 missense mutation on DNA repair and cancer susceptibility. Cancer Cell. 2004;6:139–150. doi: 10.1016/j.ccr.2004.06.024. [DOI] [PubMed] [Google Scholar]
  • 51.Yoshioka K, Yoshioka Y, Hsieh P. ATR kinase activation mediated by MutSalpha and MutLalpha in response to cytotoxic O6-methylguanine adducts. Mol Cell. 2006;22:501–510. doi: 10.1016/j.molcel.2006.04.023. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES